TriangleEnasidenib (NCT06176989)
Enasidenib trial for Metastatic Chondrosarcoma (NCT06176989). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged 18–120 with selected sinonasal or skull-base cancers carrying an IDH2 R140 or R172 mutation. Disease must recur or progress after systemic therapy for recurrent or metastatic cancer. Locally advanced tumors must lack curative surgery or radiation options.
The idea: block mutant IDH2 with enasidenib. Patients take 100 milligrams orally daily in continuous 28-day cycles. Researchers measure time without progression. Research blood collection is required; biopsy exemptions are possible.
This phase 2 study plans 40 patients. Charalampos Floudas leads at NIH in Bethesda, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.